119 related articles for article (PubMed ID: 9293790)
21. Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies.
DeNardo GL; Mahe MA; DeNardo SJ; Macey DJ; Mirick GR; Erwin WD; Groch MW
Nucl Med Commun; 1993 Jul; 14(7):587-95. PubMed ID: 8355919
[TBL] [Abstract][Full Text] [Related]
22. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
23. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Carr CE; Mirick GR; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
[TBL] [Abstract][Full Text] [Related]
24. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
25. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ
Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
[TBL] [Abstract][Full Text] [Related]
26. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
27. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
Breitz HB; Fisher DR; Wessels BW
J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
[TBL] [Abstract][Full Text] [Related]
28. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Blakkisrud J; Løndalen A; Dahle J; Turner S; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):55-61. PubMed ID: 27587710
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
30. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
[TBL] [Abstract][Full Text] [Related]
31. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
32. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.
Wahl RL; Kroll S; Zasadny KR
J Nucl Med; 1998 Aug; 39(8 Suppl):14S-20S. PubMed ID: 9708566
[TBL] [Abstract][Full Text] [Related]
33. 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.
Hattori N; Gopal AK; Shields AT; Fisher DR; Gooley T; Pagel JM; Press OW; Rajendran JG
Nucl Med Commun; 2012 Dec; 33(12):1225-31. PubMed ID: 22955187
[TBL] [Abstract][Full Text] [Related]
34. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
Gates VL; Carey JE; Siegel JA; Kaminski MS; Wahl RL
J Nucl Med; 1998 Jul; 39(7):1230-6. PubMed ID: 9669400
[TBL] [Abstract][Full Text] [Related]
35. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
O'Donnell RT; Leigh BR; Christensen SD; Goldstein DS; Kukis DL; Shen S; Yuan A; DeNardo DA; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1999 Jun; 14(3):167-76. PubMed ID: 10850301
[TBL] [Abstract][Full Text] [Related]
37. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of solid cancers: A review.
Kairemo KJ
Acta Oncol; 1996; 35(3):343-55. PubMed ID: 8679266
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
[TBL] [Abstract][Full Text] [Related]
40. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
Shen S; DeNardo GL; Sgouros G; O'Donnell RT; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2102-6. PubMed ID: 10616892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]